State Street’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,183,716
| Closed | -$204M | – | 4852 |
|
|
2021
Q3 | $204M | Buy |
1,183,716
+77,846
| +7% | +$10.2M | 0.01% | 829 |
|
|
2021
Q2 | $139M | Buy |
1,105,870
+108,937
| +11% | +$13.7M | 0.01% | 1061 |
|
|
2021
Q1 | $135M | Sell |
996,933
-140,878
| -12% | -$18.2M | 0.01% | 1008 |
|
|
2020
Q4 | $146M | Sell |
1,137,811
-9,340
| -0.8% | -$1.1M | 0.01% | 899 |
|
|
2020
Q3 | $129M | Buy |
1,147,151
+18,148
| +2% | +$1.81M | 0.01% | 846 |
|
|
2020
Q2 | $108M | Sell |
1,129,003
-347,923
| -24% | -$33.5M | 0.01% | 913 |
|
|
2020
Q1 | $133M | Buy |
1,476,926
+14,910
| +1% | +$1.16M | 0.01% | 730 |
|
|
2019
Q4 | $77.5M | Buy |
1,462,016
+38,464
| +3% | +$1.75M | 0.01% | 1214 |
|
|
2019
Q3 | $56.2M | Sell |
1,423,552
-122,671
| -8% | -$5.32M | ﹤0.01% | 1368 |
|
|
2019
Q2 | $63.5M | Sell |
1,546,223
-294,292
| -16% | -$12.2M | ﹤0.01% | 1328 |
|
|
2019
Q1 | $85.7M | Buy |
1,840,515
+376,334
| +26% | +$16.5M | 0.01% | 1104 |
|
|
2018
Q4 | $63.8M | Sell |
1,464,181
-83,614
| -5% | -$4.18M | 0.01% | 1207 |
|
|
2018
Q3 | $88.6M | Buy |
1,547,795
+14,085
| +0.9% | +$692K | 0.01% | 1155 |
|
|
2018
Q2 | $74.4M | Buy |
1,533,710
+68,721
| +5% | +$2.5M | 0.01% | 1237 |
|
|
2018
Q1 | $57.3M | Buy |
1,464,989
+133,480
| +10% | +$5.67M | ﹤0.01% | 1343 |
|
|
2017
Q4 | $56.5M | Buy |
1,331,509
+220,458
| +20% | +$8.27M | ﹤0.01% | 1358 |
|
|
2017
Q3 | $41.5M | Sell |
1,111,051
-20,773
| -2% | -$721K | ﹤0.01% | 1494 |
|
|
2017
Q2 | $34.4M | Buy |
1,131,824
+97,199
| +9% | +$2.82M | ﹤0.01% | 1609 |
|
|
2017
Q1 | $27.4M | Buy |
1,034,625
+91,451
| +10% | +$2.41M | ﹤0.01% | 1717 |
|
|
2016
Q4 | $24.1M | Buy |
943,174
+56,219
| +6% | +$1.78M | ﹤0.01% | 1759 |
|
|
2016
Q3 | $32.1M | Buy |
886,955
+146,552
| +20% | +$4.85M | ﹤0.01% | 1463 |
|
|
2016
Q2 | $25.2M | Sell |
740,403
-112,659
| -13% | -$3.66M | ﹤0.01% | 1597 |
|
|
2016
Q1 | $22.5M | Buy |
853,062
+336,459
| +65% | +$9.78M | ﹤0.01% | 1649 |
|
|
2015
Q4 | $25.2M | Buy |
516,603
+181,749
| +54% | +$6.54M | ﹤0.01% | 1548 |
|
|
2015
Q3 | $8.34M | Buy |
334,854
+51,216
| +18% | +$1.54M | ﹤0.01% | 2269 |
|
|
2015
Q2 | $8.97M | Buy |
283,638
+38,178
| +16% | +$1.23M | ﹤0.01% | 2328 |
|
|
2015
Q1 | $9.34M | Buy |
245,460
+11,183
| +5% | +$445K | ﹤0.01% | 2246 |
|
|
2014
Q4 | $9.13M | Buy |
234,277
+19,085
| +9% | +$665K | ﹤0.01% | 2259 |
|
|
2014
Q3 | $6.51M | Sell |
215,192
-337,253
| -61% | -$9.5M | ﹤0.01% | 2401 |
|
|
2014
Q2 | $18.8M | Buy |
552,445
+444,966
| +414% | +$14.9M | ﹤0.01% | 1844 |
|
|
2014
Q1 | $3.71M | Buy |
107,479
+16,968
| +19% | +$766K | ﹤0.01% | 2748 |
|
|
2013
Q4 | $3.59M | Buy |
+90,511
| New | +$2.18M | ﹤0.01% | 2761 |
|
State Street's XLRN Position: Q4 2021 in Review
State Street sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,183,716 shares — an estimated $204M sold.
State Street first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $204M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- State Street reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- State Street sold 1,183,716 Acceleron Pharma shares in Q4 2021, an estimated $204M.
- State Street first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- State Street's Acceleron Pharma position peaked at $204M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on State Street's 13F filing for Q4 2021, filed 14 Feb 2022.